(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Colorectal Cancer pipeline constitutes 145+ key companies continuously working towards developing 150+ Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Colorectal Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Colorectal Cancer Market.

 

Some of the key takeaways from the Colorectal Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Colorectal Cancer treatment therapies with a considerable amount of success over the years. 
• Colorectal Cancer companies working in the treatment market are Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others, are developing therapies for the Colorectal Cancer treatment 

• Emerging Colorectal Cancer therapies in the different phases of clinical trials are- 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others are expected to have a significant impact on the Colorectal Cancer market in the coming years.   
• In March 2022, ALX Oncology Inc. will begin a Phase II Study (With Safety Run-In) of ALX148 in Combination with Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Colorectal Cancer in Collaboration with Merck Sharp & Dohme Corp. and Eli Lilly and Company
• In October 2022,  In order to start a Phase 1 clinical trial for LYL845, Lyell Immunopharma declared that the US Food and Drug Administration (FDA) had approved its Investigational New Drug (IND) application. Patients with relapsed and/or refractory metastatic or locally advanced melanoma will be the initial participants in a phase I trial that will later include participants with non-small cell lung cancer and colorectal cancer
• In September 2022, Botensilimab, an Fc-enhanced anti-CTLA-4 that stimulates innate and adaptive immune responses, has begun a global Phase II programme, according to Agenus. For the treatment of microsatellite stable colorectal cancer, these trials include ACTIVATE-Colorectal, a Phase II research evaluating botensilimab both alone and in combination with balstilimab (anti-PD-1)
• In September 2022, In a Phase II clinical trial, BioNTech reported that its personalised mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) has successfully treated the first patient with colorectal cancer

 

Colorectal Cancer Overview

Any cancer that affects the colon and rectum is referred to as colorectal cancer, often known as bowel cancer, colon cancer, or rectal cancer.Tumours that develop in the lining of the large intestine lead to colorectal cancer. It affects both men and women frequently. After age 50, there is an increased risk of having colorectal cancer.

 

Get a Free Sample PDF Report to know more about Colorectal Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight

 

Emerging Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:

• 188RNL-BAM: Plus Therapeutics
• PCS11T: Processa Pharmaceutic als
• HLX13: Shanghai Henlius Biotech
• Adagrasib: Mirati Therapeutics
• XL092: Exelixis
• EO2040: Enterome
• Etrumadenant: Arcus Biosciences
• LYL845: Lyell Immunopharma
• Geptanolimab: Apollomics
• HDM201: Novartis Pharmaceuticals
• TP-1454: Sumitomo Pharma Oncology
• NT219: Purple Biotech Ltd.
• NKTR-255: Nektar Therapeutics
• Evorpacept (ALX148): ALX Oncology Inc.
• CPGJ 602 Sunshine: Guojian Pharmaceutical
• Trastuzumab deruxtecan: Daiichi Sankyo
• GRT-C901: Gritstone Bio, Inc
• SHR-1701: Suzhou Suncadia Biopharmace uticals Co., Ltd.
• Trilaciclib: G1 Therapeutics
• Lumakras (sotorasib): Amgen
• MRTX849: Mirati Therapeutics

 

Route of Administration

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

 

Colorectal Cancer Pipeline Therapeutics Assessment

• Colorectal Cancer Assessment by Product Type
• Colorectal Cancer By Stage and Product Type
• Colorectal Cancer Assessment by Route of Administration
• Colorectal Cancer By Stage and Route of Administration
• Colorectal Cancer Assessment by Molecule Type
• Colorectal Cancer by Stage and Molecule Type

 

DelveInsight’s Colorectal Cancer Pipeline Report covers around 150+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Colorectal Cancer product details are provided in the report. Download the Colorectal Cancer pipeline report to learn more about the emerging Colorectal Cancer therapies

 

Some of the key companies in the Colorectal Cancer Therapeutics Market include:

Key companies developing therapies for Colorectal Cancer are – Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics,  Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.

 

Colorectal Cancer Pipeline Analysis:

The Colorectal Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer Treatment.
• Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Colorectal Cancer drugs and therapies

 

Colorectal Cancer Pipeline Market Drivers

• Emergence of targeted therapies for mCRC treatment, technical Advancement in molecular subtyping of CRC tumors, increase in product development activities are some of the important factors that are fueling the Colorectal Cancer Market.

 

Colorectal Cancer Pipeline Market Barriers

• However, limitations in understanding secondary resistance, high Cost of Treatment
• Challenges related to precision oncology in mCRC management and other factors are creating obstacles in the Colorectal Cancer Market growth.

 

Scope of Colorectal Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others
• Key Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others
• Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies
• Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers 

 

Request for Sample PDF Report for Colorectal Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1	Colorectal Cancer Report Introduction
2	Colorectal Cancer Executive Summary
3	Colorectal Cancer Overview
4	Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment
5	Colorectal Cancer Pipeline Therapeutics
6	Colorectal Cancer Late Stage Products (Phase II/III)
7	Colorectal Cancer Mid Stage Products (Phase II)
8	Colorectal Cancer Early Stage Products (Phase I)
9	Colorectal Cancer Preclinical Stage Products
10	Colorectal Cancer Therapeutics Assessment
11	Colorectal Cancer Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Colorectal Cancer Key Companies
14	Colorectal Cancer Key Products
15	Colorectal Cancer Unmet Needs
16	Colorectal Cancer Market Drivers and Barriers
17	Colorectal Cancer Future Perspectives and Conclusion
18	Colorectal Cancer Analyst Views
19	Appendix
20	About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services